跳至主要内容
临床试验/CTRI/2017/05/008476
CTRI/2017/05/008476招募中4 期

A prospective, open-label, single-arm, multicenter, post marketing surveillance study to evaluate safety and performance of MIRUSâ?¢Disposable Hemorrhoids Stapler in the treatment of prolapsed Hemorrhoids. - MIRUSâ?¢ Disposable Hemorrhoids Stapler

Meril Endo Surgery Pvt Ltd0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Each potential subject must satisfy all of the following criteria to be enrolled in the study:
  • 1. Male and female subjects who are 18 to 80 years of age.
  • 2. Those subjects with late grade II hemorrhoids and unlikely to respond to one or two sessions of rubber band ligation (RBL) and/or conservative treatment.
  • 3. Subjects with grade III (prolapsing internal hemorrhoids requiring manual reduction) and/or grade IV (irreducible prolapse) are suitable candidate with stapled hemorrhoidopexy.
  • 4. Subject must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • 5. Subject must follow the post-operative follow-up visits for 6 months.

排除标准

  • Any potential subject who meets any of the following criteria will be excluded from participating in the study:
  • 1. Any female subject, who is pregnant, suspected pregnancy at the time of screening.
  • 2. Subjectâ??s tissue thickness found to be less than 0.75mm or greater then 1.5mm, or where the internal diameter of the rectum will not be able to accommodate the instrument and
  • accessories.
  • 3. Subjectâ??s tissue has undergone multiple injections of hardening agent at hemorrhoids.
  • 4. The subject has a history of fecal incontinence.
  • 5. The subject has an active or a history of infection requiring antibiotics at the intended operative site within 30 days prior to the planned surgery date.
  • 6. The subject has a history of venous thrombosis or pulmonary embolism.
  • 7. The subject has a history of coagulopathy.
  • 8. The subject has taken aspirin, anti coagulation and/or anti platelet therapies (e.g. Warfarin, Lovenox) within 7 days prior to the planned date of surgery.
  • 9. The subject has existing anal stenosis/severe mucosal edema or any other co-morbidities which in the opinion of the investigator will not be appropriate for the study.
  • 10. Subject undergone multiple injections in tissue, using hardening agents or with history of acutely prolapsed thrombosed piles associated anal fistulas (abnormal connection between anal canal & skin), anal fissures (anal
  • ulcer), abscess (pus under the skin surrounding the anus) or rectal prolapse.

研究者

发起方
Meril Endo Surgery Pvt Ltd

相似试验

撤回
不适用
A prospective, single-arm, open-label, multicenter clinical investigation to assess the safety and performance of SILKline breast implants in healthy female subjects
NL-OMON48726Polytech Health&Aesthetics GmbH30
进行中(未招募)
4 期
A study to evaluate the efficacy and safety of Fixed Dose Combination of Glycopyrronium, Formoterol Fumarate, Budesonide in patients with chronic obstructive pulmonary disease.
CTRI/2023/10/058791upin Limited
进行中(未招募)
1 期
A clinical study to confirm the doses of selexipag to be used in children with pulmonary arterial hypertensioMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertension
EUCTR2018-000145-39-DEActelion Pharmaceuticals Ltd60
进行中(未招募)
1 期
A clinical study to confirm the doses of selexipag to be used in children with pulmonary arterial hypertensioPulmonary arterial hypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2018-000145-39-PLActelion Pharmaceuticals Ltd55
已完成
2 期
A prospective, multicenter, open-label, single-arm, Phase 2 study to investigate the safety, tolerability and pharmacokinetics of selexipag in children with pulmonary arterial hypertensio4. PAH belonging to Nice 2013 Updated Classification Group 1 (including Down syndrome) and of one of the following etiologies: - Idiopathic (iPAH)- Heritable (hPAH)- aPAH-CHD: - PAH with co-incidental CHD - Post-operative PAH (persisting / recurring / developing = 6 months after repair of CHD)- Drug or toxin induced- PAH associated with HIV - PAH associated with connective tissue disease (PAH aCTD)I27.0Primary pulmonary hypertension
DRKS00015024Actelion Pharmaceuticals Ltd.63